2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2730

Impact of Disease Flare Perception on Work Productivity and Treatment Satisfaction in Patients with Psoriatic Arthritis in Real World Setting
Abstract Number: 2731

Illness Perceptions and Health-Related Quality of Life in Patients with Axial Spondyloarthritis and Other Forms of Chronic Back Pain in the Spondyloarthritis Caught Early (SPACE)-Cohort
Abstract Number: 2732

Meaningful Involvement of Patients in the Development of a Core Outcome Set for Psoriatic Arthritis
Abstract Number: 2733

Fatigue, Pain and Patient Global Assessment Fluctuate Substantially in Spondyloarthropathy Patients with Stable Disease According to Basdai
Abstract Number: 2734

Is Disease Activity Associated with Negative Illness Perceptions in Early Axial Spondyloarthritis Patients in the Spondyloarthritis Caught Early (SPACE)-Cohort?
Abstract Number: 2735

Regional Variability of Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: An Analysis from a Prospective, Observational Registry
Abstract Number: 2736

Do Validated Tools of Disease Activity in Ankylosing Spondylitis Measure Fibromyalgia Pain?
Abstract Number: 2737

Posttraumatic Stress Disorder and Correlates of Disease Activity Among Veterans with Ankylosing Spondylitis
Abstract Number: 2738

The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients
Abstract Number: 2739

Subclinical Ungueal Distrophy in Patients with Psoriasis without Joint Involvement: Is There Any Role for Nail Ultrasound?
Abstract Number: 2740

Cam Type Femoroacetabular Impingement Morphology Is More Frequent in Patients with Axial Spondyloarthritis
Abstract Number: 2741

Reliability and Construct Validity of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire – Independent Validation Study in a UK Cohort
Abstract Number: 2742

How Are Enthesitis, Dactylitis and Nail Involvement Measured and Reported in Recent Clinical Trials of Psoriatic Arthritis (PsA)? a Systematic Literature Review
Abstract Number: 2743

Do Specific Entheseal Points in Spa Patients Impact Patient Reported Outcomes? Implications for Clinical Practice
Abstract Number: 2744

Utilization of the Psoriasis Epidemiology Screening Tool (PEST) Questionnaire to Detect Psoriatic Arthritis in Clinical Practice: Data from the Validation of Psoriatic Arthritis Screening Tool for Korean Psoriasis Patients (VALOR) Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].